C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, announced that beginning October 1, 2026, eligible Anthem® Blue Cross® and Blue Shield® members will be the first in the United States to receive insurance coverage under a medical policy for the PrecivityAD2® blood test. This policy expands patient access to an innovative blood-based diagnostic test that helps health care professionals evaluate adults experiencing cognitive decline or other signs and symptoms associated with Alzheimer’s disease.
By providing coverage for eligible patients, the policy helps reduce financial barriers to testing and expands access to innovative diagnostic technologies when deemed medically necessary by a health care professional.
The PrecivityAD2® blood test aids health care professionals in determining the likelihood of amyloid plaques in the brain, one of the pathological hallmarks of Alzheimer’s disease.
As the second-largest health insurer in the United States, Anthem® serves approximately 40 million medical members across 14 states, including California, the Midwest (Indiana, Missouri, Ohio, Wisconsin), the South (Georgia, Kentucky, Virginia), New England (Connecticut, Maine, New Hampshire), Colorado, Nevada, and parts of New York State.
Anthem highlighted the following in its medical policy decision:
- A landmark study published in the Journal of the American Medical Association (JAMA) found that the PrecivityAD2® blood test demonstrated high agreement with brain amyloid status and correctly identified amyloid pathology in more than 90% of evaluated patients. This level of performance was comparable to more invasive cerebrospinal fluid (CSF) testing and expensive amyloid PET brain scans. The study included patients seen in primary care, where most people first seek help for memory problems, as well as those evaluated by memory specialists.
- The peer-reviewed journal “Diagnostics” published research that showed health care professionals reported increased diagnostic confidence when using the PrecivityAD2® blood test to help rule in or rule out Alzheimer’s disease. This change in clinician-reported probability of Alzheimer’s disease was also associated with meaningful adjustments in downstream clinical care, including changes in plans for Alzheimer’s disease medications as well as additional brain amyloid testing.
Dr. Joel Braunstein, President and CEO of C2N Diagnostics, said, “This is an important milestone for patients, families, and health care professionals. Anthem’s coverage of the PrecivityAD2® blood test is a meaningful step toward reducing financial barriers and improving access to evidence-based, clinically validated Alzheimer’s disease diagnostics. High-quality blood biomarker testing can facilitate timely evaluation through a minimally invasive, widely available approach. We appreciate Anthem for their policy and hope this decision encourages other private and public insurers to follow so that more people across the country can benefit from this diagnostic advance.”
Dana Abendschein, a patient in Valley Park, Missouri who received the PrecivityAD2® test that helped his clinician confirm his Alzheimer’s disease diagnosis, said, “With insurance coverage of diagnostics, we can help more patients receive an early and accurate diagnosis. I was able to get answers for my memory issues and then get on treatment. My goal is to keep doing the things I love to do for as long as I can do them.”
The PrecivityAD2® test is available in all 50 states and the District of Columbia and can be ordered by a health care professional. Interested health care professionals can visit www.precivityad.com or call 1.877.C2N.DIAG (226.3424) to learn more.
About C2N Diagnostics, LLC
C2N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help health care researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 200 Alzheimer’s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer’s Association, and other non-profits and consortiums in addition to research and distribution partnerships with leading labs around the world including Grupo Fleury, Healius, Mediford, and Mayo Clinic Laboratories. Over 90,000 Precivity®-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.
The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery Foundation, BrightFocus Foundation, Alzheimer’s Association and The Michael J. Fox Foundation. For more information, visit www.c2n.com.
About the PrecivityAD2® Test
The PrecivityAD2® test is a clinically and analytically validated blood test used to assist in the evaluation of adult patients, aged 50 years and older, with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer’s disease or other forms of cognitive decline. The PrecivityAD2® test uses immunoprecipitation followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) to quantify β-Amyloid 1-42 (Aβ42) and β-Amyloid 1-40 (Aβ40) peptide concentrations, and phosphorylated and non-phosphorylated tau protein at amino acid threonine, position 217 (p-tau217 and np-tau217) peptide concentrations in human K2-EDTA plasma. A statistical algorithm combines the Aβ42/40 ratio and the p-tau217/np-tau217 ratio x 100 (%p-tau217) to generate the Amyloid Probability Score 2 (APS2) result, a numeric value ranging from 0-100 to identify the likelihood of brain amyloid presence, a pathological hallmark of Alzheimer’s disease. For more information, see www.precivity.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260709196435/en/
Media gallery
